Bank of New Hampshire Sells 172 Shares of iShares Biotechnology ETF (NASDAQ:IBB)

Bank of New Hampshire decreased its position in iShares Biotechnology ETF (NASDAQ:IBB) by 6.0% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,712 shares of the financial services provider’s stock after selling 172 shares during the quarter. Bank of New Hampshire’s holdings in iShares Biotechnology ETF were worth $359,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Darwin Wealth Management LLC purchased a new stake in iShares Biotechnology ETF in the 3rd quarter valued at about $29,000. Highline Wealth Partners LLC purchased a new stake in shares of iShares Biotechnology ETF during the third quarter valued at approximately $30,000. Ashton Thomas Securities LLC purchased a new position in iShares Biotechnology ETF in the third quarter worth $36,000. Modus Advisors LLC bought a new position in iShares Biotechnology ETF in the 4th quarter valued at $41,000. Finally, Voisard Asset Management Group Inc. purchased a new stake in shares of iShares Biotechnology ETF during the 3rd quarter valued at $59,000. Hedge funds and other institutional investors own 62.45% of the company’s stock.

iShares Biotechnology ETF Price Performance

Shares of NASDAQ:IBB opened at $135.47 on Wednesday. The company’s 50-day moving average is $138.42 and its 200 day moving average is $142.10. iShares Biotechnology ETF has a fifty-two week low of $123.60 and a fifty-two week high of $150.57.

iShares Biotechnology ETF Cuts Dividend

The business also recently announced a dividend, which was paid on Friday, December 20th. Shareholders of record on Tuesday, December 17th were paid a $0.0624 dividend. The ex-dividend date of this dividend was Tuesday, December 17th.

iShares Biotechnology ETF Company Profile

iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.